Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with b-cell chronic lymphocytic leukemia

Leukemia

Volumn 26, Issue 7, 2012, Pages 1564-1575

  Knight, S J L ^a,b   Yau, C ^c   Clifford, R ^d   Timbs, A T ^d   Sadighi Akha, E ^b   Dreau H M ^d   Burns, A ^a,d   Ciria, C ^e   Oscier, D G ^f   Pettitt, A R ^g   Dutton, S ^e   Holmes, C C ^b,c   Taylor, J ^a,b   Cazier, J B ^b   Schuh, A ^a,d  

^a NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

B CLL; Clonal architecture; Copy neutral loss of heterozygosity; Genome imbalance; Genome wide arrays; OncoSNP

Indexed keywords

ADULT; AGED; ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE LOSS; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOMICS; HETEROZYGOSITY; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 84863785266     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.13     Document Type: Article

References (48)

1. Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using singlenucleotide polymorphism arrays. Nat Biotechnol 2000; 18: 1001-1005.
2. Campbell PJ, Stephens PJ, Pleasance ED, O’Meara S, Li H, Santarius T et al. Identification of somatically acquired rearrangements in cancer using genomewide massively parallel paired-end sequencing. Nat Genet 2008; 40: 722-729.
3. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-724.
4. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322: 1377-1380.
5. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
6. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
7. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
8. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
9. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189-195.
10. Yau C, Mouradov D, Jorissen RN, Colella S, Mirza G, Steers G et al. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol 2010; 11: R92.
11. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review. National Cancer Institute: Bethesda, MD, 1975-2008. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
12. CRUK. http://info.cancerresearchuk.org/cancerstats/types/leukaemia/.
13. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413-5417.
14. Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009; 50: 510-513.
15. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242-1245.
16. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322-3329.
17. Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009; 114: 5307-5314.
18. Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002; 99: 300-309.
19. Hallek M. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. Blood (ASH Ann Meet Abstr) 2009; 114: 535.
20. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
21. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
22. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009; 69: 5553-5559.
23. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949.
24. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 2007; 27: 2240-2252.
25. Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007; 109: 5079-5086.
26. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-1277.
27. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28-40.
28. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008; 68: 1012-1021.
29. Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011; 25: 489-497.
30. Ouillette P, Collins R, Shakhan S, Li J, Li C, Shedden K et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res 2011; 17: 6778-6790.
31. Sellick GS, Wade R, Richards S, Oscier DG, Catovsky D, Houlston RS. Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood 2008; 111: 1625-1633.
32. Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens UM et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007; 109: 1202-1210.
33. Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 2008; 10: 442-451.
34. Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008; 112: 1993-2003.
35. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet 2010; 203: 161-168.
36. Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a highresolution genomic screening of newly diagnosed patients. Leukemia 2010; 24: 211-215.
37. Gunnarsson R, Mansouri L, Isaksson A, Goransson H, Cahill N, Jansson M et al. Array-based genomic screening at diagnosis and follow-up in chronic lymphocytic leukemia. Haematologica 2011; 96: 1161-1169.
38. Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011; 118: 3051-3061.
39. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008; 319: 336-339.
40. Bateman CM, Colman SM, Chaplin T, Young BD, Eden TO, Bhakta M et al. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood 2010; 115: 3553-3558.
41. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362-367.
42. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.
43. Sun W, Wright FA, Tang Z, Nordgard SH, Van Loo P, Yu T et al. Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res 2009; 37: 5365-5377.
44. Greenman CD, Bignell G, Butler A, Edkins S, Hinton J, Beare D et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 2010; 11: 164-175.
45. Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W et al. Allelespecific copy number analysis of tumors. Proc Natl Acad Sci USA 2010; 107: 16910-16915.
46. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010; 20: 68-80.
47. Letouze E, Allory Y, Bollet MA, Radvanyi F, Guyon F. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol 2010; 11: R76.
48. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y et al. Detection of large-scale variation in the human genome. Nat Genet 2004; 36: 949-951.